TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00989534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed restricted bedtimes
Description: Sleep restricted to 5 hours per night for 8 nights

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction with circadian misalignment
Description: Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
Study: NCT00528645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study: NCT04431700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Description: Anti-inflammatory diet with increased vegetables, fruit, plant polyphenols, lean proteins, foods rich in omega-3s and unsaturated fats as well as decreased in processed refined foods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular diet
Description: Focus on food journal and recording all food intake.
Study: NCT01489891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
Study: NCT04463966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
Study: NCT02168829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Study: NCT03129139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide™Capsules
Description: Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide™Capsules
Description: Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide™Capsules
Description: Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
Study: NCT02022189

Intervention type: PROCEDURE
Intervention: Renal Biopsy
Study: NCT04218149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Block with bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Block with bupivacaine
Study: NCT01581138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: 400 mg tablets twice daily for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: 400 mg tablets twice daily for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: 1125 mg tablets twice daily for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: 1125 mg tablets twice daily for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
Study: NCT02383004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
Study: NCT03548532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G210 incubator
Description: very stable culture temperature, up to 0.1°C, in both arms
Study: NCT02097901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: Rotator Cuff Repair AND Microfracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NO microfracture
Description: Rotator Cuff Repair without microfracture
Study: NCT03948165

Intervention type: PROCEDURE
Intervention: Distal Transradial Access
Description: The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
Study: NCT01970345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1
Description: IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
Study: NCT03548532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G210 incubator
Description: very stable culture temperature, up to 0.1°C, in both arms
Study: NCT04205227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: ENB003 is selective Endothelin B Receptor Antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD1
Study: NCT03242915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 IV every 3 weeks
Study: NCT01885299

Intervention type: RADIATION
Intervention: SRS/SBRT
Description: Intervention varies by condition being treated.
Study: NCT03641755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine may help to stop the growth of some types of cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine may help to stop the growth of some types of cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine may help to stop the growth of some types of cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Sapacitabine may help to stop the growth of some types of cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
Study: NCT04504253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate loose powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
Study: NCT03527420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Twelve weeks of aerobic exercise training
Study: NCT04965025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-stage urethroplasty with graft inlay in first stage
Description: Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-stage urethroplasty with graft inlay in second stage
Description: Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
Study: NCT03723655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study: NCT03733626

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system
Description: ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system
Description: Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
Study: NCT05813574

Intervention type: OTHER
Intervention: Observational patient reported outcomes
Description: Of COVID-19 patients
Study: NCT01970345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/saline
Description: Placebo
Study: NCT02819830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Combined strength and aerobic exercise
Study: NCT03461276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABvac40
Description: ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminium hydroxide as adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminium hydroxide) without the conjugate.
Study: NCT00538200

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Supplements (Fortisip)
Description: These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Advice
Description: Standard dietary advice
Study: NCT00542243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride (5mg) will be given once per day for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given once a day for 6 months.
Study: NCT06520254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: A 30-minute massage session will be applied in the following structures:~* Flexor hallucis longus muscle,~* Flexor digitorum longus muscle,~* Tibialis posterior muscle,~* Semitendinosus muscle,~* Semimembranosus muscle,~* Gluteus maximus muscle,~* Longissimus muscle,~* Levator costarum muscles 1-5 During the massage session basic Swedish massage techniques were used.
Study: NCT04540250

Intervention type: OTHER
Intervention: questionnaire
Description: conventional intra-oral examination and questionnaire
Study: NCT04805229

Intervention type: OTHER
Intervention: Retrospective analysis of opioid use after surgery
Description: Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
Study: NCT00267904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Caffeinated coffee and decaffeinated coffee ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banana
Description: Banana ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olives
Description: Olives ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temp. manip.
Description: Manipulate temperature at skin of the back
Study: NCT00994084

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Kids-Houston program
Description: Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
Study: NCT01425424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D
Study: NCT01853644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: 1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
Study: NCT02657512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 40 mg/day (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 40 mg/day (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban 40 mg/day (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and activated charcoal
Description: rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and activated charcoal
Description: rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and activated charcoal
Description: rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
Study: NCT01177579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Description: 4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
Study: NCT00619203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol and paracetamol
Description: glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebos, one po, one suppository

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol and glycerol
Description: 35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol
Description: glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
Study: NCT00647491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 20 mg sc eow

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg sc eow

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 80 mg sc eow

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc eow
Study: NCT02108990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT04971278

Intervention type: BEHAVIORAL
Intervention: Supportive care program
Description: Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.

Intervention type: BEHAVIORAL
Intervention: Supportive care program
Description: Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
Study: NCT00493298

Intervention type: DRUG
Intervention: Tysabri
Description: According to the local prescribing information
Study: NCT04184739

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My Braces App
Description: An App designed to support patients undertaking orthodontic treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Braces App
Description: An App designed to support patients undertaking orthodontic treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Braces App
Description: An App designed to support patients undertaking orthodontic treatment.
Study: NCT03741452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transversalis fascia plane block
Description: patient controlled analgesia devices with tramadol
Study: NCT04417322

Intervention type: OTHER
Intervention: observation of serum A.actinomycetemcomitans levels
Description: Analysis of serum A.actinomycetemcomitans levels

Intervention type: OTHER
Intervention: observation of serum A.actinomycetemcomitans levels
Description: Analysis of serum A.actinomycetemcomitans levels
Study: NCT03650309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
Study: NCT01096277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: oral tablets 100 mg per day for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, one per day for two weeks

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: no intervention
Study: NCT02810574

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive brain stimulation (active)
Description: Neuroconn DC-STIMULATOR PLUS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive brain stimulation (sham)
Description: Neuroconn DC-STIMULATOR PLUS
Study: NCT01014533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dispensed to subject.
Description: Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin dispensed to subject.
Description: After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.